|
High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Clinical research trials and High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma. High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma clinical trial. Subjects typically recieve the finest healthcare available for their High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "H" Clinical Trials Conditions > High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
For Condition: stage 4 adult immunoblastic large cell lymphoma,stage 3 adult diffuse mixed cell lymphoma,stage 4 adult diffuse mixed cell lymphoma,stage 3 grade III follicular large cell lymphoma,stage 3 adult immunoblastic large cell lymphoma,stage 4 grade III follicular large cell lymphoma,stage 4 adult diffuse large cell lymphoma,stage 3 adult diffuse large cell lymphoma
Status: No longer recruiting
Sponsor(s): British National Lymphoma Investigation ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether high dose chemotherapy plus bone marrow transplantation is more effective than high dose chemotherapy alone for intermediate- or high-grade non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of high dose chemotherapy with or without bone marrow transplantation in treating patients who have intermediate- or high-grade non-Hodgkin's lymphoma.
Details: OBJECTIVES: I. Assess the value of early intensification with autologous bone marrow transplantation or stem cell support in patients with poor prognosis intermediate or high grade non-Hodgkin's lymphoma. PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified by age (under 50 vs 50 and over), bone marrow involvement (yes vs no), and country. All patients receive cyclophosphamide, doxorubicin, and vincristine on day 1 and prednisone on days 1-5. Courses repeat every 21 days. Patients receive a minimum of 6 courses of treatment in the absence of disease progression and unacceptable toxicity. Arm I: Patients receive carmustine IV over 2 hours on day 1 in week 9 or 10. Etoposide and cytarabine IV are administered over 30 minutes on days 2-5. Melphalan IV is administered over 5 minutes on day 6. Patients receive cryopreserved bone marrow or peripheral blood stem cells on day 7. Arm II: Patients continue conventional therapy. Patients are followed at 8-9 weeks and 6 months. PROJECTED ACCRUAL: This study will accrue 500 patients.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 16 Years/65 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed intermediate or high grade adult non-Hodgkin's lymphoma: Follicular large cell lymphoma; Diffuse mixed cell lymphoma; Diffuse large cell lymphoma; Diffuse immunoblastic lymphoma - Poor prognostic features defined as the presence of 2 or 3 of the following: Stage III/IV; Lactase dehydrogenase greater than normal; ECOG performance status 2-4 [A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.] --Prior/Concurrent Therapy-- - At least 5 years since prior systemic therapy for cancer --Patient Characteristics-- - Age: 16 to 65 - Performance status: See Disease Characteristics - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: See Disease Characteristics - Renal: Not specified - Other: No other medical condition prohibiting intensive therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DavidLinch, Study Chair, British National Lymphoma Investigation
Royal Free Hospital
Hampstead, London, England, NW3 2QG
United Kingdom
St. Mary's Hospital
London, , W2 1NY
United Kingdom
King George Hospital
Ilford, Essex, , IG3 8YB
United Kingdom
Oxford Radcliffe Hospital
Oxford, England, 0X3 9DU
United Kingdom
Maidstone Hospital
Maidstone, England, ME16 9QQ
United Kingdom
Saint Richards Hospital
Chichester, , P019 4SE
United Kingdom
Hillingdon Hospital
Uxbridge, England, UB8 3NN
United Kingdom
Charles University Hospital
Prague (Praha), , 128 08
Czech Republic
Bristol Haematology and Oncology Centre
Bristol, England, BS2 8ED
United Kingdom
Sheffield Teaching Hospitals
Sheffield, England, S1O 2JF
United Kingdom
Law Hospital
Carluke UK, , ML8 5ER
United Kingdom
Pontefract General Infirmary
West Yorks, England, WF8 1PL
United Kingdom
Oldchurch Hospital
Romford, England, RM7 OBE
United Kingdom
Ullevall Hospital
Oslo, , N-0407 4
Norway
Huddersfield Royal Infirmary
Huddersfield, West Yorks, England, HD3 3EA
United Kingdom
University College London Medical School
London, England, W1N 8AA
United Kingdom
Pembury Hospital
Royal Tunbridge Wells, Kent, England, TN2 4QJ
United Kingdom
Northwick Park Hospital
Harrow, England, HA1 3UJ
United Kingdom
Southport and Formby District General Hospital
Merseyside, England, PR8 6NJ
United Kingdom
New Cross Hospital
Wolverhampton, England, WV10 0QP
United Kingdom
Nottingham City Hospital NHS Trust
Nottingham, England, NG5 1PB
United Kingdom
East Surrey Hospital
Redhill, , RH1 5RH
United Kingdom
Kent and Canterbury Hospital
Canterbury, England, CT2 7NR
United Kingdom
Weston Park Hospital
Sheffield, England, S1O 2SJ
United Kingdom
Epsom General Hospital
Epsom Surrey, , KT19 7EG
United Kingdom
Queen Elizabeth Hospital
King's Lynn, , PE30 4ET
United Kingdom
Good Hope Hospital Trust
West Midlands, England, B75 7RR
United Kingdom
Royal Marsden Hospital
Sutton, England, SM2 5PT
United Kingdom
Grantham and District Hospital
Grantham, , NG31 8DG
United Kingdom
Ysbyty Gwynedd
Bangor, Wales, LL57 2PW
United Kingdom
Altnagelvin Area Hospital
Londonderry, Northern Ireland, BT47 1SB
United Kingdom
City Hospital - Birmingham
Birmingham, England, B18 7QH
United Kingdom
Sandwell District General Hospital
West Bromwich, England,
United Kingdom
Ipswich Hospital NHS Trust
Ipswich, England, IP4 5PD
United Kingdom
Charing Cross Hospital
London, England, W6 8RF
United Kingdom
Derbyshire Royal Infirmary
Derby, England, DE1 2QY
United Kingdom
St. Bartholomew's Hospital
London, England, EC1A 7BE
United Kingdom
Southmead Hospital
Bristol, England, BS10 5NB
United Kingdom
Rigshospitalet
Copenhagen, , 2100
Denmark
Royal Bournemouth Hospital
Bournemouth, , BH7 7DW
United Kingdom
Mount Vernon Hospital
Northwood, England, HA6 2RN
United Kingdom
University of Tromso
Tromso, , N-9037
Norway
West Middlesex Hospital
Middlesex, , N18 1QZ
United Kingdom
Rotherham District General Hospital-NHS Trust
Rotherham, , S60 2UD
United Kingdom
Queen's Hospital, Burton
Burton upon Trent, England, DE14 3QH
United Kingdom
Leeds Teaching Hospital Trust
Leeds, England, LS1 3EX
United Kingdom
Norwegian Radium Hospital
Oslo, , N-0310
Norway
Middlesex Hospital- Meyerstein Institute
London, England, WIT 3AA
United Kingdom
Saint Bartholomew's Hospital
London, England, EC1A 7BE
United Kingdom
Countess of Chester Hospital
Chester, England, CH2 1UL
United Kingdom
Royal Liverpool and Broadgreen Hospitals
Liverpool, England, L7 8XP
United Kingdom
University Hospitals of Leicester
Leicester, England, LE1 5WW
United Kingdom
Birmingham Heartlands and Solihull NHS Trust (Teaching)
Birmingham, England, B9 5SS
United Kingdom
Belfast City Hospital Trust
Belfast, Northern Ireland, BT9 7AB
United Kingdom
Stoke Mandeville Hospital
Aylesbury-Buckinghamshire, England, HP21 8AL
United Kingdom
Cheltenham General Hospital
Cheltenham, England, GL53 7AN
United Kingdom
Chase Farm Hospital
Enfield, , NG31 8DG
United Kingdom
Staffordshire General Hospital
Stafford, , ST16 3SA
United Kingdom
Whipps Cross Hospital
London, England, E11 1NR
United Kingdom
Scunthorpe General Hospital
Scunthorpe, , DN15 7BH
United Kingdom
Derriford Hospital
Plymouth, England, PL6 8DH
United Kingdom
Royal United Hospital
Bath, England, BA1 3NG
United Kingdom
Newham General Hospital
London, , E13 8RU
United Kingdom
Clatterbridge Centre for Oncology NHS Trust
Merseyside, England, L63 4JY
United Kingdom
Royal South Hants Hospital
Southampton, England, SO14 0YG
United Kingdom
Walton General Hospital
Liverpool, , L9 1AE
United Kingdom
Milton Keynes General Hospital
Milton Keynes, England, MK6 5LD
United Kingdom
Christie Hospital N.H.S. Trust
Manchester, England, M20 4BX
United Kingdom
Aarhus Amtssygehus
Aarhus, , DK 8000
Denmark
University College London
London, England, W1W 7EJ
United Kingdom
St. Georges Hospital Medical School
London, England, SW17 ORE
United Kingdom
Torbay Hospital
Torquay Devon, England, TQ2 7AA
United Kingdom
Additional Information:
Study ID Numbers: CDR0000066645; BNLI-LY02,EU-98039
Study Start Date: January 1993
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003578
Other Stage 3 Adult Immunoblastic Large Cell Lymphoma Studies:
1. Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma
2. High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
3. Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Older Patients With Previously Untreated Non-Hodgkin's Lymphoma
4. Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
5. Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
Related Studies:
Other stage 3 adult immunoblastic large cell lymphoma Clinical Trials
Other England Clinical Trials
Other London Clinical Trials
High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
|
|
|
|
|
|
|
|